Publications
247
Citations
9,765
Est. group size
—
Recurring co-author estimate
Active years
20
Publishing since 2007
Shadia I. Jalal conducts clinical cancer research focused primarily on lung cancer, including non-small cell and small cell lung cancer. The work centers on immunotherapy (treatments that harness the immune system against tumors), clinical trials of new drug combinations, and biomarkers that predict treatment response and side effects. Additional projects address esophageal and gastric cancers, cancer genetic testing, and novel approaches such as fasting-based diets to enhance therapy.
Publication activity has been steady over the decade with year-to-year fluctuation, showing a peak in 2023 and continued output through recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Brief Report: A Pilot Study Evaluating the Feasibility, Safety, and Compliance With a Fasting-Mimicking Diet in Patients With Metastatic Non–Small Cell Lung Cancer
Clinical Lung Cancer · 2026
- FUEL-IT Lung: Fasting to unleash and enhance lung cancer immunotherapy—A VA Lung Precision Oncology Program trial.
Journal of Clinical Oncology · 2026
- Guidance conformance of mainstream germline cancer testing by oncology providers in the Veterans Health Administration.
Journal of Clinical Oncology · 2026
- Evaluating inflammatory biomarkers as predictors of outcomes and immune-related adverse events (irAE) in the Big Ten Cancer Research Consortium (BTCRC) LUN16-081 phase II clinical trial.
Journal of Clinical Oncology · 2025
- Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025
- A Pilot Study of Pulmonologists’ Receptivity to Artificial Intelligence Use
American Journal of Respiratory and Critical Care Medicine · 2025
- Advances in Multimodality Management of Localized Non-Small Cell Lung Cancer
Seminars in Respiratory and Critical Care Medicine · 2025
- Abstract B017: Phase 2 Study of NP-G2-044, a Novel Fascin Inhibitor, in Combination with Anti-PD-1 Therapy in Patients with Solid Tumors Resistant to Prior Anti-PD-1 Therapy
Cancer Immunology Research · 2025
- Durable responses in ICI-refractory or acquired resistance: Phase 2 study of NP-G2-044 combined with anti-PD-1 therapy.
Journal of Clinical Oncology · 2025
- Brief Report: A phase II pilot study evaluating the feasibility, safety, and compliance with a fasting-mimicking diet in patients with metastatic non-small cell lung cancer
SSRN Electronic Journal · 2025
- Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non–Small Cell Lung Cancer a Systemic Review and Meta-analysis
Clinical Lung Cancer · 2025
- A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies.
Journal of Clinical Oncology · 2024
- Comparative oncology chemosensitivity assay for personalized medicine using low-coherence digital holography of dynamic light scattering from cancer biopsies
Scientific Reports · 2024
- Observing cross-species cross-cancer chemosensitivity signatures with dynamic-contrast OCT
2024
- P1.13A.03 MOZART: Phase II Trial of Monalizumab, Durvalumab, and Platinum-based Chemotherapy for First-Line Treatment of Extensive Stage SCLC
Journal of Thoracic Oncology · 2024
- Journal of Clinical Oncology×47
- Journal of Thoracic Oncology×13
- Cancer Research×5
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Journal of Pain and Symptom Management×4
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile